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SINTESIS, PENCIRIAN DAN AKTIVITI  PERENCATAN 
KOLINESTERASE BAGI SEBATIAN BARU HETROSIKLIK SPIRO 
BERGRAF PIPERIDON 
 
ABSTRAK 
 
Lima siri baru spiro-oksindola-pirrolizina dan hibrid  pirolidina telah disintesis 
menggunakan tindak balas facil satu-pot tiga komponen linear atau kitaran asid α-
amino,  isatin dan pelbagai dipolarofil N-akriloil-bisarilidenapiperidin-4-on. 
 
Tindak balas ini menghasilkan terbitan baru heterosiklik mono-spiro  dan bis-spiro 
dengan menukar nisbah bahan pemula  daripada 1:1:1 daripada 1:2:2 dipolarofil, asid 
α-amino dan isatin. Siklotambahan-spiro ini telah dicirikan dengan  menggunakan 
analisis unsur, teknik spektroskopi IR, 1-D dan 2-D NMR serta data  kristalografi X-
Ray. 
 
Selain itu, semua  sebatian baru yang disintesis telah diuji aktiviti terhadap penyakit  
Alzheimer menggunakan asai kolorimetrik Ellman. Dalam asai ini, aktiviti perencat 
kolinesterase  terhadap sebatian yang disintesis telah  disaring secara  in vitro 
menggunakan enzim asetilkolinesterase (AChE) daripada belut elektrik dan enzim 
butirilkolinesterase (BChE) daripada serum kuda, yang mempunyai peranan utama  
dalam manifestasi dan perkembangan penyakit Alzheimer. 
 
Keputusan menunjukkan heterosiklik mono-spiro mempunyai aktiviti perencatan 
yang lebih baik terhadap kedua-dua enzim berbanding dengan heterosiklik bis-spiro. 
 xxiv 
 
Sebatian 9i, 10g, 12b, 9e, 10e dan 12e menunjukkan aktiviti perencatan tertinggi di 
dalam siri berkaitan setanding dengan aktiviti bagi dadah piawai, galantamina. 
 
Kajian simulasi komputer permodelan molekul yang menggunakan struktur kristal 
Torpedo californica (TcAChE) dan BChE (hBChE) manusia turut menunjukkan 
orientasi dan mekanisme interaksi pengikatan sebatian yang paling aktif di dalam 
tapak aktif gorge pada reseptor AChE dan BChE. Kajian permodelan ini memberikan 
keputusan yang bertepatan dengan yang diperoleh melalui kajian in vitro. 
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SYNTHESIS, CHARACTRIZATION AND CHOLINESTERASE INHIBITORY 
ACTIVITY OF NOVEL PIPERIDONE GRAFTED SPIRO HETEROCYCLES 
 
ABSTRACT 
 
Five new series of new spiro-oxindole-pyrrolizine and pyrrolidine hybrids were 
synthesized employing facile one-pot three-component reaction of linear or cyclic             
α-amino acids, isatin and various derivatives of N-acryloyl-bis arylidene piperidin-4-
ones dipolarophiles. 
 
These reactions afforded new mono-spiroheterocycles and bis-spiroheterocycles by 
changing the ratio of the starting materials from 1:1:1 to 1:2:2 of dipolarophiles,                   
α-amino acid and isatin. These spiro-cycloadducts were further elucidated using 
elemental analysis, IR, 1-D and 2-D NMR spectroscopy techniques as well as X-Ray 
crystallographic data.  
 
The newly synthesized compounds were also evaluated for their activity against 
Alzheimer’s disease using Ellman’s colorimetric assay. In this assay the cholinesterase 
inhibitory activity of the aforementioned compounds were screened in vitro against 
acetylcholinesterase enzyme (AChE) from electric eel and butyrylcholinesterase enzyme 
(BChE) from equine serum, which have the major roles in the manifestation and 
progression of Alzheimer’s disease.  
 
xxvi 
 
The results revealed that mono-spiroheterocycles displayed better inhibitory activity 
against both enzymes in comparison to bis-spiroheterocycles, therein compounds 9i, 
10g, 12b, 9e, 10e and 12e showed the highest inhibitory activities among their relevant 
series comparable to the activity of the standard drug, galanthamine.     
 
Novel computer based molecular modeling simulation studies using crystal structure of 
Torpedo californica AChE (TcAChE) and human BChE (hBChE) were also employed 
to disclose the orientation and binding interaction mechanism of the active compounds 
inside the active site gorge of AChE and BChE receptors.  
 1 
 
CHAPTER ONE 
 INTRODUCTION 
 
1.1. 1, 3-Dipolar cycloaddition  
1,3-Dipolar cycloaddition, also known as the Huisgen reaction, provides an efficient 
method for the synthesis of various types of ﬁve-membered heterocyclic compounds, 
such as pyrrolidines and pyrrolizines, owing to its high regio- and stereo-selectivity.1 
This type of reaction takes place between a 1,3-dipole (1)  and a substituted alkene as 
dipolarophile (2), to form a five-membered heterocyclic ring (3) (Figure 1.1). While 1,2-
disubstituted alkenes are incorporated into 1,3-dipolar cycloaddition reactions, new 
chiral centers can be formed in a stereospecific manner due to “syn” addition of dipole 
(1) to the double bond of dipolarophile (2). Depending on the structure of the dipole, 
this type of reaction can furnish complex heterocycles with up to four new contiguous 
chiral centers in a single step. 2-4 
 
 
Figure 1.1: Schematic representation of 1,3-dipolar cycloaddition reactions 
 
The asymmetric version of this reaction using either chiral dipolarophile or even chiral 
catalysts is relatively new methodology, which offers a powerful and reliable synthetic 
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methodology to access enantiomerically pure five-membered heterocyclic rings in regio- 
and stereo controlled fashion. 5, 6 
 
1.1.1. 1,3-Dipoles 
The 1,3-dipole, bears a positive and a negative charge distributed over three atoms. The 
most common atoms incorporated in the 1,3-dipole are nitrogen, carbon, oxygen or 
sulfur. As depicted in Figure 1.2, 1,3-dipoles can be classified into nitrones (4), 
azomethine ylides (5), nitrile oxides (6), carbonyl ylides (7), azides (8), imines (9), 
diazoalkanes (10), and diazoacetates (11) which are widely used to afford variety of  
biologically active target heterocycles.7 
 
 
 
Figure 1.2: Structures of various 1,3-dipoles 
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1.1.2. Dipolarophiles 
The dipolarophile is a reactive multiple bond system. α, β-unsaturated aldehydes and 
ketones (12), allylic alcohols and halides (13), vinylic ethers (14) and alkynes (15) are 
examples of dipolarophiles. It must be pointed out that dipolarophiles incorporating 
conjugated double bonds such as dipolarophile (12) can exist in two main 
conformations, cis and trans, which can have a major impact on the outcome of an 
asymmetric 1,3-dipolar cycloaddition reaction (Figure 1.3). 
 
 
 
Figure 1.3: Structures of various dipolarophiles 
 
1.2. Multi-component reaction of azomethine ylides 
Multi-component reactions offer a wide range of possibilities for the efficient synthesis 
of highly complex molecules in a single operational step. These reactions eliminate the 
need for several workups and purification steps, enabling a great saving of both solvents 
and reagents. Multi-component reactions have attracted considerable attention since an 
initial report in 1850 by Strecker, who introduced a novel method for the synthesis of 
amino acids.8 Passerini further discovered that isonitriles can participate in 
multicomponent reactions and this finding formed the basis of the well-known Ugi 
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reaction.9 The development of new multi-component reactions often enables efficient 
and convenient entry into interesting structures. 
 
The multi-component, 1,3-dipolar cycloaddition of azomethine ylides to an electron-
deﬁcient dipolarophile is an important method for the construction of nitrogen 
containing ﬁve-membered pyrrolidine and pyrrolizine heterocyclic rings in a single step. 
Pyrrolidines and pyrrolizines are among the major building blocks used for the synthesis 
of natural products and pharmacologically active heterocyclic compounds. 10, 11 
Azomethine ylides are generated in situ from decarboxylative condensation of either 
aldehydes or ketones with α-amino acids under reﬂux. 12 As depicted in Figure 1.4, these 
dipolar molecules contain a negatively charged atom, usually a carbanion, directly 
attached to a nitrogen atom with positive charge, in which both atoms have full octets of 
electrons.13, 14  
 
 
 
Figure 1.4: Schematic representation of azomethine ylides 
 
1.3. Biological significance of spiro oxindoles, pyrrolidines and pyrrolizines 
The spiro oxindoles can be obtained from the cycloaddition reaction of azomethine 
ylides generated in situ from isatin and α-amino acids, to dipolarophiles bearing 
exocyclic double bonds. This heterocyclic system is the core structure of many 
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pharmacological agents and natural alkaloids.15 Spirotryprostatin A (16), a natural 
product isolated from the fermentation broth of Aspergillus fumigatus, has been 
identified as a novel inhibitor of microtubule assembly.16  Spirotryprostatin B (17) 
inhibits the growth of human chronic myelogenous leukemia K562 cells and human 
promyelocytic leukemia HL-60 cells.17 Pteropodine (18) and isopteropodine (19) have 
been shown to modulate the function of muscarinic and serotonin receptors.18 
Strychnofoline (20) belongs to a class of natural products isolated from the leaves of 
Strychnos usambarensis, which displays antimitotic activity against cultures of mouse 
melanoma and Ehrlich tumor cells (Figure 1.5).19 A prominent structural feature of these 
and related spirotryprostatin alkaloids is the presence of a spiro-[pyrrolidin-3,3'-
oxindole] nucleus.20 
 
 
Figure 1.5: Structures of various spiro oxindoles 
 
Spiro oxindole derivatives were also found to be potent aldose reductase inhibitors 
(ARIs), which help to treat and prevent diabetic complications arising from elevated 
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levels of sorbitol. Some spiro pyrrolidines are potential antileukemic and anticonvulsant 
agents and possess antiviral and local anesthetic activities. 21 It is also worth to note that 
several natural spiro oxindoles act as potent non-peptide inhibitor of the p53–MDM2 
interaction. 22  
 
Kumar et al. reported novel three-component tandem reactions of cyclic mono ketones, 
isatin and sarcosine to form di-spiropyrrolidines, which represented pronounced 
biological activity.23 Fokas et al., has reported synthesis of a library of spiro 
[pyrrolidine-2,30-oxindole] compounds, which can be used as bioactive agents, bio-
separation agents or pesticides.24 
 
Pyrrolidine and pyrrolizine ring system are also found in a large number of biologically 
active natural and artificial compounds.25 As shown in Figure 1.6, polyhydroxylated 
pyrrolidines (21-25) such as DMPD (21), Hyacinthacines (22), Alexine (23), 
Broussonetine C(24), Glycomimetics (25)  have drawn considerable interest in recent 
years, primarily due to their ability to inhibit glycosidases.26 Glycosidases are valuable 
therapeutic agents in treatment of many serious diseases like diabetes 27, cancer 28, and 
viral infections such as HIV.29 Besides, novel synthetic pyrrolizines also showed potent 
anti-mycobacterial,30 anti-inflammatory 31 and anti-tubercular activities.30  
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Figure 1.6: Structures of various biologically active pyrrolidines 
 
1.4. Alzheimer’s disease (AD) 
Alzheimer’s disease (AD) is the most common form of dementia, accounting for 50–
60% of all the cases. The prevalence of dementia is lower than 1% in individuals aged 
60–64 years, however displays an almost exponential increase with age, with 24% to 
33% prevalence in individuals aged 85 years or more (Figure 1.7).32  
 
 
Figure 1.7: The diagram for representation of increase in prevalence of AD with age 
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1.4.1. Definition of Alzheimer’s disease 
AD is a progressive disease with debilitating consequences for the patients and their 
families.33 Epidemiologically, AD is classified into early-onset familial AD (FAD) and 
late-onset sporadic AD, or SAD. FAD is associated with mutations in three genes 
coding for amyloid precursor protein (APP), presenilin-1 (PS-1) and presenilin-2 (PS-2), 
which are inherited. FAD most commonly occurs in patients between 40 and 65 years of 
age and is characterized by a rapid progression.34 Late onset SAD accounts for the 
majority (95%) of AD cases in people above 65 years.  
 
This neurodegenerative disorder typically begins with subtle and poorly recognized 
failure of memory that slowly becomes more severe and eventually incapacitating. Other 
common finding comprises progressive impairment of cognitive functions including 
memory loss, confusion, poor judgment, language disturbance, withdrawal and 
hallucinations. Death usually results from general inanition, malnutrition, and 
pneumonia. At advanced stages of the disease, AD patients also exhibit behavioral 
disturbances including agitation, irritability, anxiety, delusions and depression. The 
typical clinical duration of the disease is 8–10 years. 32, 35 
 
1.4.2. Major Alzheimer’s disease risk factors 
The major risk factors of AD are classified into: firstly, family history, in which 
individuals with brother or sister affected by AD are more likely to develop this 
disease.36, 37  
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Secondly, individuals with ɛ4 form of gene apolipoprotein E, (APOE- ɛ4), are at 
increased risk of developing AD.38 APOE-ɛ4 is one of three common forms of the 
APOE gene, which provides the blueprint for a protein that carries cholesterol in the 
bloodstream. Everyone inherits one form of the APOE gene from each parent. Those 
who inherit one APOE-ɛ4 gene have increased risk of developing AD and of developing 
it at an earlier age than those who inherit the APOE-ɛ2 or APOE-ɛ3 forms of the APOE 
gene. Thirdly, cardiovascular disease risk factors such as physical inactivity, high 
cholesterol (especially in midlife), diabetes, smoking and obesity, are associated with a 
higher risk of developing AD and other dementias.39-41 Then, social engagement such as 
remaining mentally and socially active and consuming a diet low in saturated fats and 
rich in vegetables, may support brain health and prevent developing AD 42, 43 and lastly, 
head trauma and Traumatic Brain Injury (TBI) are associated with an increased risk of 
AD and other dementias. Moderate head injuries are associated with twice the risk of 
developing AD compared with no head injuries, and severe head injuries are associated 
with 4.5 times the risk (Figure 1.8).44  
 
 
Figure 1.8: Schematic representation of healthy brain and severely affected AD brain 45 
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1.4.3. Pathology of Alzheimer’s disease 
The pathology of AD has been studied intensely in the last 20 years. Animal models 
have provided valuable information to understand the mechanisms. Typical pathological 
phenomena are extracellular senile plaques, consisting amyloid beta peptides (Aβ), and 
intracellular neurofibrillary tangles composed of phosphorylated au protein. Both Aβ 
peptides and au proteins are normal cellular constituents, which in AD both take an 
abnormal fibrillary structure, associated with a poor solubility in aqueous media (Figure 
1.9).  
 
Figure 1.9: Amyloid plaques and neurofibrillary tangles in Alzheimer’s disease 46 
 
Aforementioned extracellular senile plaques, physically damage the cholinergic neurons 
in the basal forebrain leading to deficiency in cholinergic neurotransmission in the 
hippocampus and cerebral cortex and contributes to the cognitive deficit of AD.47, 48  
 
1.4.4. Cholinergic hypothesis  
The cholinergic hypothesis was the ﬁrst theory proposed to explain AD and has led to 
the development of the drugs currently approved to treat mild to moderate AD. Based on 
the ﬁnding, loss of cholinergic activity is commonly observed in the brains of AD 
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patients.49 This hypothesis postulates that the cognitive impairments experienced by AD 
patients results from the deficiency in cholinergic neurotransmission and acetylcholine 
generation decline.50  
 
1.4.5. Acetylcholine (ACh) and butrylylcholine (BCh) 
Acetylcholine (ACh, 26) is an organic, polyatomic cation that acts as a neurotransmitter 
in both the peripheral nervous system (PNS) and central nervous system (CNS) in many 
organisms including humans. It is an ester acid and possess the chemical formula of 
“CH3COO(CH2)2N
+(CH3)3” with systematic name of “2-acetoxy-N,N,N-trimethylethan-
aminium”. In contrary to acetylcholine, butyrylcholine (27) is not a physiological 
substrate in human brain but a synthetic compound, which is used as a substrate to 
differentiate between the two types of cholinesterase enzymes (Figure 1.10). 
 
 
Figure 1.10: Acetylcholine (26) and butrylylcholine (27) 
 
The rational way to enhance the cholinergic neurotransmission is to inhibit the 
cholinesterase enzymes responsible for the metabolic breakdown of acetylcholine 
(ACh). Acetylcholinesterase inhibitors (AChEI) can enhance cholinergic 
neurotransmission by increasing acetylcholine (ACh) availability in the synaptic cleft.51  
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1.4.6. Cholinesterases  
In vertebrates, there are two types of cholinesterase, acetylcholinesterase (AChE) and 
butyrylcholinesterase (BChE), which can be distinguished based on their substrate 
specificities, distribution in various tissues and sensitivity toward various inhibitors. 
AChE (EC 3.1.1.7) (Figure 1.11) is a serine hydrolase enzyme located in peripheral 
and/or central nervous cholinergic system.52 This enzyme is a membrane-bound enzyme, 
which is mainly found in the brain, muscles, erythrocytes and cholinergic neurons. It is 
an essential enzyme in the human body to degrade acetylcholine and the terminate 
neurotransmission impulses.53 Recent studies revealed that AChE could also play a key 
role in accelerating senile amyloid β-peptide (Aβ) plaques deposition.54 AChE has high 
catalytic activity since each enzyme is able to degrade about 25,000 molecules of 
acetylcholine per second. 55 
 
Figure 1.11: Molecular representation of AChE enzyme 56 
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AChE is the target of natural toxins such as alkaloids and polypeptide toxins, synthetic 
pesticides and warfare agents, as well as drugs designed to combat neuromuscular 
disorders, such as myasthenia gravis, glaucoma and Alzheimer’s disease.57  
 
Another cholinesterase, butyrylcholinesterase (BChE) (Figure 1.12), is also involved in 
metabolic degradation of acetylcholine and differs from AChE for tissue distribution 
and sensitivity to wide variety of substrates and inhibitors.52  
 
The specific function of BChE is not clearly known but it is suggested to act as a 
scavenger of cholinergic toxins in addition to have an auxiliary role in synaptic 
neurotransmission. 58 This enzyme is found in the intestine, liver, kidney, heart, lung, 
and blood serum and plays a major role in the metabolism of ester containing 
compounds. BChE can displace AChE in acetylcholine degradation when it is inhibited 
or absent. Normally, in the healthy brain, AChE is predominant but in AD brain, BChE 
activity rises while AChE activity remains unchanged or diminished. 59 Many species 
such as human, horse, mice exhibit high BChE activity in their plasma, while rat has 
higher AChE activity than BChE in its plasma. AChE and BChE share 65% amino acid 
sequence homology. 60 
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Figure 1.12: Molecular representation of BChE enzyme 61  
 
1.4.7. AChE and BChE structural specifications 
The overall architecture of the AChE and BChE enzymes is quite similar. The active site 
is located at the bottom of a 20 Å deep cavity named as “aromatic gorge”. Substrate and 
inhibitor guidance down the aromatic gorge is facilitated by hydrophobic interactions 
with aromatic residues lining the gorge wall such as phenylalanine (Phe), tryptophan 
(Trp) and tyrosine (Tyr).62  
 
The overall structure of BChE is very similar to that of AChE. However, in the active 
site of BChE aromatic residues such as tryptophan (Trp) and phenylalanine (Phe) are 
replaced with hydrophobic ones such as leucine (Leu) and valine (Val), making BChE 
more appropriate to accommodate bulkier substrates and inhibitors. 63 AChE and BChE 
possess a catalytic triad (CT) composed of Ser200, His440 and Glu327 residues in 
TcAChE as well as His438, Ser198 and Glu325 in hBChE enzyme.64  
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The mechanism of substrate binding to catalytic triad site plausibly is through 
nucleophilic attack of serine hydroxyl moiety to carbonyl group of the substrate to give 
an acyl-enzyme intermediate. Subsequently, a water molecule de-acylates serine residue 
by hydrolyzing its ester linkage to the substrate (Scheme 1.1). 
 
 
 
Scheme 1.1: Schematic representation acetylcholine substrate hydrolysis in AChE 
catalytic triad 
 
Four other binding sub-sites incorporate into proper orientation of the choline substrates 
in the catalytic cavity. Using TcAChE residue numbering, these sub-sites are: 
 
(i)  A three-pronged oxyanion hole, formed by the backbone amides of Gly117, 
Gly118, and Ala201 that stabilizes the negative charge developed at the C=O moiety of 
the substrate in the acylation/de-acylation process. 65  
 
(ii) The aromatic rings of Trp84 and Phe330 that stabilize the quaternary ammonium 
function of the choline moiety through π-π interactions.66  
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(iii)  A concave hydrophobic pocket (the acyl-binding pocket) consisting of residues 
Phe288 and Phe290 where are located in the so-called acyl loop in which the acetyl or 
propanoyl moiety of the substrate is bound (Figure 1.13). 67 and,  
 
(iv)  A peripheral anionic site composed of aromatic Tyr 70, Asp72, Tyr 121, Trp279 
and Tyr334 residues to guide the substrate to catalytic triad.65  
 
 
Figure 1.13: Peripheral anionic site (yellow), choline binding site (green), oxyanion 
hole (maroon) and catalytic triad (orange) residues of TcAChE in complex with 
donepezil (blue) 56 
 
As mentioned earlier, most differences between BChE and AChE are confined to the 
residues lining the gorge wall in peripheral anionic site, where the aromatic residues are 
replaced with hydrophobic one. In addition, acyl-binding pocket residues in AChE, 
Phe288 and Phe290, are replaced by Leu286 and Val288, in BChE. These changes make 
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it possible for the binding of the bulkier substrates moiety in BChE in contrast to AChE 
(Figure 1.14). 63  
 
 
Figure 1.14: Peripheral anionic site (yellow), choline binding site (green), oxyanion 
hole (maroon) and catalytic triad (orange) residues of hBChE in complex with its BCh 
substrate (blue) 61 
 
1.4.8. Cholinesterase inhibitor drugs to treat AD  
Drugs capable of inhibiting cholinesterase enzymes, plausibly affect central cholinergic 
function, by increasing level of ACh, thus improving cognition and even some of the 
behavioral problems experienced by AD patients. Marketed acetylcholinesterase 
inhibitors (AChEI’s) (Figure 1.15) often used in combination with diverse conventional 
drugs such as antidepressants, antioxidants, and neuro-protectants. 68 
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Typical analysis of new acetylcholinesterase inhibitors (AChEIs) are performed by 
assaying in vitro activity using Ellman’s method. Based on this assay, the structure-
activity relationship (SAR) is determined. 69 Ex vivo and in vivo as well as toxicology 
studies will be performed on the most active inhibitors at in vitro stage to estimate their 
bioavailability and pharmacodynamics profile. 
 
AChE inhibitors inhibit AChE via two different mechanisms: firstly, competitive, 
reversible mechanism, by interacting with the active site of the enzyme through a 
network of polar and hydrophobic molecular interactions, and secondly, non-
competitive, irreversible mechanism, through strong covalent binding to the active site 
of enzyme, thus destructing catalytic site of the enzyme. All the AD drugs are classified 
as reversible inhibitors whereas pesticides and nerve gases are belong to latter class. 
 
Many AChE inhibitors used clinically for the treatment of AD are alkaloidal natural 
products or natural product analogues, such as rivastigmine, galanthamine and huperzine 
A, along with many of the synthetic AChE inhibitors such as donepezil and tacrine. 
However, after a long period of using these AChE inhibitors to treat mild or moderate 
AD in clinical practice, a profile of adverse effects was gradually recognized, including 
increased rates of heart attack, acute liver toxicity, and hip fracture in older adults. Most 
of the efforts in AChE inhibitor discovery concentrated on structural modification of the 
existing drugs or a combination of active substructures, while the resulting compounds 
might suffer the risk of adverse effects due to the similarities in the scaffold. 68, 70 
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Tacrine (28) was the first AChE inhibitor permitted by the FDA to enter the medical 
market although its adverse effects such as hepatotoxicity and gastrointestinal disorders, 
led to its early withdrawal from the market. Tacrine is cholinesterase inhibitor with high 
selectivity toward plasma BChE.57 
 
Donepezil (29) the reversible, non-competitive acetylcholinesterase inhibitor (AChEI) 
was approved and became available for use in patients with mild to moderate AD in 
February 1997 and is now being prescribed worldwide.  
 
 
Figure 1.15: Structures of the acetyl cholinesterase inhibitors as FDA approved 
Alzheimer’s disease therapeutics. 
 
 
Rivastigmine (30) is a reversible dual inhibitor of both AChE and BChE with a short 
plasma half-life but a relatively longer duration of ChE inhibition.71 This inhibitor 
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displays speciﬁc activity for central AChE over peripheral AChE and currently being 
used for the treatment of AD and memory dysfunction. Recent investigations indicated 
that rivastigmine also produces signiﬁcant beneﬁcial effect in patients with vascular 
dementia or dementia associated with Parkinson's disease. 72 
 
Galanthamine (31) is an alkaloid extracted from several species of amaryllidaceae. It is a 
centrally acting, selective, competitive, and reversible AChEI, which in addition to 
inhibit AChE with a mild potency behaves as an allosteric potentiating ligand at 
nicotinic receptors contributing to neuroprotection. It has been shown that galanthamine 
maintains long-term cognitive function and delays emergence of behavioral symptoms. 
73, 74 It is as effective as tacrine in the treatment of AD, but it has a lower toxicity and 
prevents neuronal damage generated by reactive oxygen species (ROS) and nitrogen 
species, such as hydrogen peroxide (H2O2) and nitric oxide (NO) in vitro.  On the basis 
of these premises, novel classes of AChE inhibitors (AChEIs) targeting the peripheral 
site have emerged as promising disease-modifying anti-AD drug candidates.75  
 
1.5. Molecular modeling simulation  
Molecular modeling technology is extensively used in different stages of the drug 
discovery procedure to represent the binding orientation template of an active 
substrate/inhibitor into its relevant receptor and predict the binding affinity of newly 
design drugs to the receptor.76  
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Pioneering research works in the area of molecular docking date back into the early 
1980s. However, it took at least a decade for this technology to become popular among 
computational chemists and pharmaceutical researchers.77 Molecular docking procedure 
typically consists of two interrelated task: (i) to sample possible lowest energy 
conformational states of the protein-ligand complex and (ii) to calculate of the free 
energy of these complex to produce a score, which can be further correlated to 
biological activities or other function, the so-called scoring.78  
 
Practically, identification of novel compound by using in silico methods is faster and 
economical in contrast to traditional approaches.79 Among the most commonly used 
ligand screening tools, docking analysis have been used extensively to predict the 
binding orientation and affinities of many potent enzyme inhibitors as well as receptor 
antagonists. Many drugs developed partly by computer-aided drug design methods are 
in late-stage of clinical trials or have now reached the market.80  
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1.6. Problem statement 
Nowadays, to use cholinesterase inhibitor drugs such as donepezil or galanthamine is 
the most practiced approach for symptomatic improvement of cognitive impairments in 
the individuals suffering from Alzheimer’s disease. Despite the tremendous efforts in 
search of novel disease modifying agents working via β-amyloid or tau pathways, none 
is clinically available due to their adverse effects. Besides, limited number of potent 
cholinesterase inhibitor drugs, keeps the search for new inhibitors going worldwide. In 
the present study, novel piperidone grafted spiropyrrolizine and spiropyrrolidine 
derivatives were synthesized, thoroughly characterized and evaluated for their inhibitory 
activities against cholinesterase enzymes. In addition, the molecular interactions and 
orientation of most active inhibitors with cholinesterase enzymes were also studied. 
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1.7. Objectives 
1. To synthesize a library of new biologically active spiro heterocycles employing 
eco-friendly, one-pot multi component reaction methodology  
 
2. To elucidate and characterize the structure of newly synthesized compounds using 
elemental analysis as well as 1D and 2D NMR spectroscopy techniques 
 
3. To evaluate the cholinesterase inhibitory activities of synthesized compounds 
against AChE and BChE enzymes using colorimetric Ellman’s method 
 
4. To perform the molecular modelling studies on the most active inhibitors to 
disclose the binding interaction and orientation inside their relevant enzymes 
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CHAPTER TWO 
MATERIALS AND METHODS 
 
2.1. Chemicals and solvents 
The chemicals and solvents used in the synthesis and characterization of the synthesized 
compounds are as follows: acetic acid glacial, AR grade; benzaldehyde; 3-
nitrobenzaldehyde, 99%; o-anisaldehyde, 98%; 2-fluorobenzaldehyde, 97%;                   
4-fluorobenzaldehyde, 98%; 2-chlorobenzaldehyde, 98.5%; 4-chlorobenzaldehyde, 
98.5%; 2,4-dichlorobenzaldehyde, 98.5%; 2-hydroxy-5-nitro-benzaldehyde;                         
2-bromobenzaldehyde, 97%; 2-hydroxy-3-methoxybenzaldehyde; 1-naphtaldehyde, 
95%; o-tolualdehyde, 98%; p-tolualdehyde, 99%; hydroxylamine hydrochloride;              
1-(2-chloroethyl)pyrrolidine hydrochloride; 4-piperidinone monohydrate hydrochloride; 
sarcosine, 98%; 4-chloro-N-methyl-piperidine hydrochloride, 99%; L-phenylalanine;  
L-proline; piperidine, 99%; isatin; 5-chloroisatin, 95%; magnesium sulphate anhydrous 
; acetone, AR grade; chloroform, AR grade; dichloromethane, AR grade; diethyl ether, 
AR grade; dimethyl sulfoxide-d6; chloroform-d1; methanol-d4; petroleum ether, AR 
grade; ethyl acetate, AR grade; 2-methoxybennzaldehyde; pyridine; potassium bromide, 
FT-IR grade; TLC silica gel 60 F254, aluminum sheets, 20 cm × 20 cm.  
 
2.2. General experimental methods 
2.2.1. Monitoring of reactions 
Silica gel-G plates (Merck) were used for TLC analysis employing a mixture of 
petroleum ether (60–80°C) and ethyl acetate as eluent. At initial steps of the reaction, 
